The Physiological and Pathophysiological Role of IL-6/STAT3-Mediated Signal Transduction and STAT3 Binding Partners in Therapeutic Applications

Biol Pharm Bull. 2023;46(3):364-378. doi: 10.1248/bpb.b22-00887.

Abstract

The interleukin 6 (IL-6) family of cytokines is defined by the usage of gp130, a common β-receptor signaling subunit, which promotes a variety of signals. They induce many biological functions on many cell types, including immune and inflammatory cells. They also exhibit hormone-like features, which are involved in homeostatic processes. Signal transducer and activator of transcription 3 (STAT3) is a significant signaling molecule fundamental in regulating IL-6/gp130 and is highly implicated in pathological conditions; therefore, STAT3 activation is tightly regulated through various mechanisms and at multiple levels. There is a large amount of information about STAT3-interacting proteins, which positively or negatively regulate STAT3 activity. This review is focused on IL-6-mediated signal transduction and the introduction of novel STAT3-binding partners. The review will help develop new strategies for clinically controlling the functions of IL-6/STAT3.

Keywords: immune disease; inflammation; interleukin 6 (IL-6); signal transducer and activator of transcription 3 (STAT3); signal transduction; therapy.

Publication types

  • Review

MeSH terms

  • Cytokine Receptor gp130
  • Cytokines
  • Interleukin-6*
  • STAT3 Transcription Factor*
  • Signal Transduction

Substances

  • Interleukin-6
  • STAT3 Transcription Factor
  • Cytokine Receptor gp130
  • Cytokines